

# EFFICACY OF FENSPIRIDE (ERESPAL) IN TREATMENT OF PATIENTS WITH SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASES

*I. V. Suvorkina*

## *Summary*

The data about the application of erespal in dosage 160 mg daily for 8 weeks in complex therapy of 21 patients with stage III chronic obstructive pulmonary diseases in phase of non-exacerbation were summarized in this report. The improvement in clinical course of diseases was registered — decreased intensity of cough and sputum production, the reduction of severity of respiratory failure. The inflammation played leading role in the mechanism of bronchial obstruction. This makes the grounds for the obligatory administration of anti-inflammatory medications in basis therapy of these patients. The increase of vital lung capacity (due to increased inspiration capacity) and the change in time indices of respiratory cycle confirm with high probability the improvement of functional condition of respiratory muscles and the increase of dynamic expansibility of lungs. Erespal is effective medication for basis therapy of patients with severe COPD.